

Catalog Number:	113105, 113106
Size:	25 tests, 100 tests
Target Name:	GRP-78, HSPA5, BiP, Endoplasmic reticulum lumenal Ca(2+)-binding protein grp78, Immunoglobulin heavy chain
Regulatory Status:	RUO

Clone:	C38
Application:	Flow Cytometry
Reactivity:	Human
Format:	iF488
Isotype:	Mouse IgG2b
Antibody Type:	Monoclonal
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA
Protein Concentration:	Supplied at a lot-specific concentration.
Storage&Handling:	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Recommended Usage:	For flow cytometric staining, it is recommended to use 5 µL of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application. iF488 has an excitation max at 491 nm and an emission max at 516 nm.
Excitation Laser:	Blue Laser (488 nm)
Isotype Control:	301603

BACKGROUND INFORMATION


Structurally, GRP78 consists of two major functional domains: an N-terminal ATPase domain and a C-terminal substrate-binding domain. The ATPase domain hydrolyzes ATP to regulate the chaperone cycle, while the substrate-binding domain interacts with unfolded or misfolded polypeptides. A C-terminal KDEL sequence ensures its retention within the ER lumen. Under certain pathological conditions, GRP78 can also be translocated to the cell surface or secreted extracellularly, where it acquires additional signaling functions.

GRP78 interacts with a wide range of ligands, including nascent polypeptides, misfolded proteins, and ER stress sensors such as PERK, IRE1, and ATF6. When expressed on the cell surface, it can bind extracellular ligands such as α 2-macroglobulin, Cripto, and certain viral proteins, mediating signaling pathways that influence cell survival, proliferation, and immune responses.

In disease, GRP78 is frequently upregulated in cancer, where it promotes tumor cell survival, resistance to apoptosis, metastasis, and therapy resistance. It is also implicated in neurodegenerative disorders, metabolic diseases, and viral infections due to its central role in protein homeostasis and stress responses.

Therapeutically, GRP78 is an attractive target for cancer treatment. Strategies include small molecules, antibodies, and peptides that inhibit its function or target GRP78-expressing cells, particularly those displaying GRP78 on their surface. Modulating GRP78 activity may also have potential in treating diseases associated with ER stress and protein misfolding.

PRODUCT DATA



COLO-205 cells were stained with iF488 Anti-Human GRP78 clone C38 (color-filled histogram) or an isotype control (right).

This product is supplied subject to the terms and conditions at www.innocyto.com/web/terms.php and may only be used as provided in the stated terms. Products are for Research Use Only.